logo-loader
viewOrthocell Ltd

Orthocell completes recruitment for shoulder tendon study with Johnson & Johnson subsidiary

The companies will begin the trial to assess the effectiveness of Ortho-ATI, a novel cell therapy developed to treat chronic tendon injuries.

Orthocell Ltd - Orthocell completes recruitment for shoulder tendon study with Johnson & Johnson subsidiary
Autologous tenocytes injection (Ortho-ATI) into the elbow using ultrasound guidance

Orthocell Ltd (ASX:OCC) has completed the recruitment for its Ortho-ATI® shoulder tendon study in collaboration with DePuy Synthes Products, part of Johnson & Johnson Medical Devices Companies.

Managing director Paul Anderson said: “We are delighted to complete the patient recruitment phase of this highly focused randomised controlled trial (RCT), designed to assess the effectiveness of Autologous Tenocyte Injection (Ortho-ATI®) as a treatment to a difficult clinical problem with limited alternatives.”

Large market opportunity

Ortho-ATI is a novel cell therapy developed to treat chronic tendon injuries and is at the forefront of a large and increasing market opportunity, estimated to be worth >US$7.7 billion and growing.

In studies conducted by Orthocell to date, Ortho-ATI has been shown to be a cost-effective long-term, nonsurgical solution for difficult to treat tendons including the rotator cuff, elbow, gluteal, patellar and achilles.

Rotator cuff tendinopathy and tear (which manifests as severe shoulder pain) is a common and often difficult injury to treat and affects more than 50% of adults over 50 years of age.

Trial details

The trial is led by Clinical Professor Allan Wang (former President of the Australian Elbow and Shoulder Society), Dr Jeff Hughes (current President of the Australian Elbow and Shoulder Society), Dr Jane Fitzpatrick, and Professor Ming Hao Zheng at the University of Western Australia (UWA).

To ensure effectiveness, patients were excluded from enrolling in the trial if they presented with any of the 16 exclusion criteria, including previous treatment injections in the prior three months; previous shoulder surgery or significant pathology of affected shoulder (eg inflammatory joint disease); or bilateral shoulder pathology.

Whilst the very detailed exclusion criteria caused delays to the anticipated recruitment timeframes, it is consistent with best practice and is not reflective of the significant patient population that is normally suitable for treatment with OrthoATI.

Quick facts: Orthocell Ltd

Price: 0.355 AUD

ASX:OCC
Market: ASX
Market Cap: $65.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orthocell preparing for launch in the US for its CelGro® bone regeneration...

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott following the news they've completed a submission to the US Food and Drug Administration (FDA) seeking 510(k) clearance for marketing its CelGro® product for dental guided bone and soft tissue regeneration...

on 26/5/20

2 min read